8-K: TNF Pharmaceuticals Secures $600,000 Strategic Investment at Premium, Partners with Prevail InfoWorks for Clinical Trials

TNF Pharmaceuticals has secured a $600,000 strategic equity investment from Prevail Partners at a 20% premium to the 30-day VWAP, and will partner with Prevail InfoWorks for upcoming clinical trials.

Summary

• TNF Pharmaceuticals has entered into a Stock Purchase Agreement with Prevail Partners, LLC, resulting in a $600,000 investment.
• Prevail Partners purchased 283,019 shares of TNF Pharmaceuticals common stock at $2.12 per share.
• The purchase price represents a 20% premium to the 30-day volume-weighted average price (VWAP) of the company's stock.
• The company intends to use the net proceeds for general corporate purposes and working capital.
• Prevail InfoWorks, an affiliate of Prevail Partners, will act as the Clinical Research Organization (CRO) for the company's next Phase 2 clinical study.
• The company's lead drug candidate, MYMD-1, is being developed to treat conditions related to immune-metabolic dysregulation.
• A previous Phase 2 study of MYMD-1 for sarcopenia showed statistically significant positive results.
• The sarcopenia treatment market is estimated to be $3.07 billion in 2024 and is expected to reach $4.02 billion by 2029.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic investment at a premium, the partnership with a reputable CRO, and the promising potential of the company's lead drug candidate. The company is also fully funded for the next two years.

Positives

• The company secured a strategic investment at a premium, indicating investor confidence.
• The partnership with Prevail InfoWorks provides access to an experienced CRO for clinical trials.
• The company is fully funded for clinical trials for the next two years.
• The company's lead drug candidate, MYMD-1, has shown promising results in a previous Phase 2 study.
• The sarcopenia treatment market is a large and growing market with no FDA-approved treatments.

Risks

• The company's ability to maintain compliance with Nasdaq listing standards is a risk.
• There are risks associated with obtaining and maintaining regulatory approvals for clinical trials.
• The timing and results of planned clinical trials are uncertain.
• The company may require additional funds for its pharmaceutical candidates.
• Increased competition in the market is a risk.
• The company's ability to protect its proprietary rights is a risk.

Future Outlook

The company is focused on advancing its clinical trials for MYMD-1 and Supera-CBD, and is fully funded for clinical trials for the next two years. The company is also looking to expand into the rapidly growing CBD market.

Management Comments

• Mitchell Glass, M.D., President and Chief Medical Officer, stated that the investment from Prevail Partners points to their confidence in MYMD-1's potential.
• Mitchell Glass, M.D., also mentioned that the company's study will benefit from Prevail InfoWorks' unique experience and expertise.

Industry Context

The announcement highlights the growing interest in novel therapies for autoimmune and inflammatory conditions, as well as the increasing focus on the sarcopenia treatment market. The partnership with a tech-enabled CRO like Prevail InfoWorks reflects a trend towards more efficient and data-driven clinical trials.

Comparison to Industry Standards

• The 20% premium on the share price is a positive signal, suggesting strong investor confidence compared to typical private placements.
• The engagement of Prevail InfoWorks as a CRO aligns with industry best practices for clinical trial management, similar to companies like ICON plc or IQVIA.
• The focus on sarcopenia treatment is timely, given the aging global population and the lack of FDA-approved treatments, similar to other companies exploring this space such as BioAge Labs.
• The estimated market size for sarcopenia treatment ($3.07 billion in 2024) is comparable to other niche therapeutic areas, indicating a significant market opportunity.

Related Party Transactions

• Prevail InfoWorks, an affiliate of Prevail Partners, will provide clinical services to TNF Pharmaceuticals.
• Prevail Partners may pay the purchase price directly to InfoWorks in satisfaction of invoices.

Stakeholder Impact

• Shareholders will benefit from the increased funding and the potential for successful clinical trials.
• Employees will have job security and opportunities for growth due to the company's financial stability.
• Customers (patients) may benefit from new treatment options for sarcopenia and other inflammatory conditions.
• Suppliers and creditors will have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will proceed with its Phase 2 clinical study for MYMD-1 in sarcopenia/frailty.
• The company will utilize the net proceeds from the private placement for general corporate purposes and working capital.
• The company will continue to develop its MYMD-1 and Supera-CBD drug platforms.

Key Dates

Keywords

TNF Pharmaceuticals, Prevail Partners, Prevail InfoWorks, MYMD-1, sarcopenia, clinical trials, equity investment, CRO, TNF inhibitor, biopharmaceutical